GET DAILY SIGNALSNeurAxis (NRXS) Delivers Record Revenue Growth in Q3 2026
Key Takeaways
- NeurAxis reported record quarterly revenue of $2.03 million for the third quarter of 2026, up 150% year over year.
- Gross margin expanded to 86.6%, supported by a higher average selling price of $1,045 per device as reimbursed treatments replaced discounted programs.
- Net loss widened to $6.5 million, or $0.52 per share, driven largely by a one-time, non-cash stock compensation charge of roughly $4.3 million.
- Two large national payers were added within 45 days, lifting the company's coverage footprint to approximately 147 million covered lives.
- Cash and cash equivalents fell to about $4.5 million at quarter-end, keeping liquidity and cash burn in focus for investors.
Putting the Quarter in Context
NeurAxis, Inc. (NRXS) is a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults. Its flagship product, IB-Stim, treats abdominal pain associated with irritable bowel syndrome (IBS) and functional dyspepsia. The third quarter marked the company's third full period operating under a permanent Category I CPT billing code, a reimbursement milestone that took effect in early 2026. This report matters because it tests whether broader insurance coverage is translating into faster device adoption, higher pricing, and a clearer path toward narrowing losses. Investors are also watching the company's cash position, given its ongoing investment in commercial expansion and clinical development. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Breaking Down the Reported Results
NeurAxis reported record third-quarter 2026 revenue of approximately $2.03 million, a 150% increase from the prior-year period and the strongest quarterly revenue in company history. Gross margin expanded by 330 basis points to 86.6%, while average selling price rose to $1,045, reflecting a shift toward higher-margin reimbursed treatments and away from discounted financial assistance programs.
Net loss widened to $6.5 million from $2.1 million a year earlier, translating to a diluted loss of $0.52 per share compared with $0.24 per share in the third quarter of 2025. The result fell short of consensus expectations, but the wider loss was driven largely by a one-time, non-cash stock compensation charge of about $4.3 million tied to restricted stock unit (RSU) settlements. Excluding that charge, the underlying cash operating loss was closer to $2.4 million, roughly in line with the prior year.
The company ended the quarter with approximately $4.5 million in cash and no debt. Operating metrics improved as well: the year-to-date prior authorization approval rate reached 32% as of September 30, up from 12% in 2025, and ordering accounts rose to 97.
Market Reaction and Investor Sentiment
Investor sentiment heading into the report had been cautious, reflecting concerns about cash burn and share dilution even as revenue accelerated. The third-quarter print reinforced that tension: the commercial model is clearly gaining traction, but the company is still investing heavily and consuming cash to support growth. The headline earnings miss — driven largely by a non-recurring stock compensation charge — added to near-term uncertainty, even though the underlying revenue and margin trends pointed in a positive direction. As a result, the market's focus remained split between the strength of the top line and the durability of the balance sheet.
Forward Outlook and Key Factors to Monitor
Looking ahead, the central question for NeurAxis is whether its accelerating revenue growth can begin to outpace spending and dilution. Management expects the recently added payer coverage to contribute modestly in the fourth quarter of 2026, with a more meaningful impact in 2027 as providers implement the new policies and the expanded sales force gains traction.
Several near-term friction points are worth monitoring. One major payer was temporarily authorizing only one device instead of the full four-device treatment course, which management expected to resolve shortly. Medicaid fee schedule implementation also remains incomplete, with CPT 64567 listed in only 27 of 50 states, a factor that could slow account activation in the coming quarters.
Investors should also watch the company's cash runway and any additional financing activity, given that cash declined to about $4.5 million and management signaled that near-term operating expenses will continue to rise. Finally, progress on the planned adult functional dyspepsia trial and the expansion of covered lives will be important signposts for whether the current commercial momentum can be sustained into 2027.
Using AI Tools for Deeper Research
In my own work, I often turn to Tickeron’s AI Screener when evaluating smaller healthcare names like this one. It lets me quickly filter for technical patterns, fundamentals, and performance metrics across thousands of stocks, which helps surface comparable ideas and confirm whether the revenue trends I’m seeing are part of a broader sector move. The tool has become a regular part of my workflow for spotting setups without spending hours on manual screening.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
NRXS in downward trend: price dove below 50-day moving average on November 02, 2026
NRXS moved below its 50-day moving average on November 02, 2026 date and that indicates a change from an upward trend to a downward trend. In 29 of 30 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on NRXS as a result. In 60 of 68 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.
The Moving Average Convergence Divergence Histogram (MACD) for NRXS turned negative on October 27, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 30 similar instances when the indicator turned negative. In 26 of the 30 cases the stock turned lower in the days that followed. This puts the odds of success at 87%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NRXS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +4.41% 3-day Advance, the price is estimated to grow further. Considering data from situations where NRXS advanced for three days, in 123 of 147 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
NRXS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 33 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 44 (best 1 - 100 worst), indicating steady price growth. NRXS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 73 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (11.641) is normal, around the industry mean (3.498). P/E Ratio (-8.211) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (14.225) is also within normal values, averaging (440.869).
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NRXS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement